Treatment Overview

Treatment Overview

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Overview</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>Immunotherapy, secretase inhibitors</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Immunotherapy, kinase inhibitors</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Immunotherapy, aggregation inhibitors</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>Gene therapy, small molecules</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>Gene silencing</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Oral</td>
<td>Convenient, widely used</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Systemic delivery</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>Non-invasive, targeted</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Long-lasting</td>
</tr>
</table>

This page provides a comprehensive overview of therapeutic approaches for neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD). [@cummings2024]

Major Therapeutic Approaches

Disease-Modifying Therapies

Treatment Overview

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Overview</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>Immunotherapy, secretase inhibitors</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Immunotherapy, kinase inhibitors</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Immunotherapy, aggregation inhibitors</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>Gene therapy, small molecules</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>Gene silencing</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Oral</td>
<td>Convenient, widely used</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Systemic delivery</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>Non-invasive, targeted</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Long-lasting</td>
</tr>
</table>

This page provides a comprehensive overview of therapeutic approaches for neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD). [@cummings2024]

Major Therapeutic Approaches

Disease-Modifying Therapies

Disease-modifying therapies aim to slow or halt disease progression by targeting underlying pathological mechanisms: [@espay2023]

Symptomatic Therapies

These treatments address symptoms rather than disease progression:

Cognitive Symptoms:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
• NMDA receptor antagonists (memantine)
• Novel glutamatergic modulators

• Dopaminergic agents (levodopa, dopamine agonists)
• MAO-B inhibitors (selegiline, rasagiline)
• COMT inhibitors (entacapone, tolcapone)

• Antipsychotics (risperidone, olanzapine)
• Antidepressants (SSRIs, SNRIs)
• Mood stabilizers

Treatment Strategies by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Emerging Treatment Modalities

Gene Therapy

• AAV-vector delivered genes
• CRISPR-based gene editing
• Antisense oligonucleotides (ASOs)
• RNA interference (RNAi)

Cell Therapy

• Stem cell transplantation
• Exosome therapy
• Cell replacement

Immunotherapy

• Active immunization (vaccines)
• Passive immunization (monoclonal antibodies)
• Adoptive cell therapy (CAR-T)

Treatment Delivery Methods

Challenges and Future Directions

Key Challenges

Future Directions

• Precision medicine approaches
• Biomarker-driven patient selection
• Early intervention strategies
• Multi-target combination therapies
• Regenerative medicine

Related Pages

• [Treatments Index](/content/treatments)
• [Treatment Rankings](/therapeutics/rankings)
• [Mechanisms](/content/mechanisms)
• [Biomarkers](/content/biomarkers)

See Also

• [Treatment Rankings](/therapeutics/rankings)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Topics

• Treatments Overview — This page
• Treatments Rankings — Ranked list by research activity
• Treatments Dashboard — Data visualizations and metrics

Summary Statistics

• Total Pages: 538 Treatments pages in this section
• Last Updated: This section is actively maintained

A-Z All Pages

• AADC Gene Therapy for Parkinson's Disease
• AADvac1 - Tau Vaccine
• AAV Gene Therapy Vectors for Neurodegenerative Diseases
• AAV Gene Therapy for Neurodegeneration
• AAV Vectors in Neurodegenerative Disease Gene Therapy
• ACI-35 Liposomal Vaccine
• AD Combination Therapy Matrix - 15x15 Scoring
• AD Therapeutic Approaches Scorecard - 28 Approaches Ranked
• [ALS Therapeutics](/therapeutics/als-therapeutics)
• ALS Treatment Strategies
• AMPA Receptor Antagonists in Neurodegenerative Disease
• AMPK Activators
• AMPK Activators for Neurodegeneration
• Acupuncture Therapy for Neurodegeneration
• Adenosine A2A Receptor Antagonist Therapy
• Aducanumab (Aduhelm)
• AhR Modulator Therapy for Neurodegenerative Diseases
• Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy
• Alpha-Lipoic Acid for Neurodegeneration
• Alpha-Synuclein Aggregation Inhibitors
• Alpha-Synuclein Aggregation Inhibitors
• Alpha-Synuclein Immunotherapy
• Alpha-Synuclein Reduction Therapies for Neurodegenerative Diseases
• Alpha-Synuclein-Targeting Therapies
• Alzheimer's Disease Treatment
• Amantadine
• Ambroxol for Neurodegeneration (GCase Chaperone Strategy)
• Ambroxol for Parkinson's Disease
• Amyloid Immunotherapy Vaccines for Alzheimer's Disease
• Amyotrophic Lateral Sclerosis (ALS) Treatment

Coverage Gaps

Underrepresented Therapeutic Categories

• PSP/CBS Treatments: No dedicated treatment overview page exists
• MSA Treatments: Missing comprehensive treatment summary
• Huntington's Disease Treatments: Need expanded coverage beyond basic symptom management
• DLB Treatments: Limited treatment options documented
• Vascular Dementia Treatments: Underrepresented in treatment rankings
• FTD Treatment Landscape: Only one page exists, needs expansion

Underdeveloped Therapeutic Modalities

• Combination Therapies: AD combination therapy matrix exists but needs expansion to other diseases
• Gene Therapy for non-PD diseases: Heavy focus on PD, limited coverage for AD/ALS gene therapy
• Cell Therapy: Need more pages on stem cell approaches across diseases
• Preventive/Prophylactic Therapies: Limited documentation of prevention strategies
• Biomarker-Driven Therapies: Only one page (ATN framework), needs expansion

Missing Cross-Links to Related Sections

• Mechanisms: Many treatments lack links to their target mechanism pages
• Clinical Trials: Need more trial status integration
• Genes/Proteins: Incomplete linking to genetic targets

Next Steps

• Create PSP Treatment Overview page
• Create MSA Treatment Overview page
• Expand FTD Therapeutic Landscape page
• Add more gene therapy pages for non-PD targets

References

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving Treatment Overview discovered through SciDEX knowledge graph analysis: